title: Eruptive milia and comedones during treatment with dovitinib.
abstract: Dovitinib (TKI258) is a multi-targeted receptor tyrosine kinase inhibitor currently under clinical trials for a wide variety of cancers. Well-known side effects include nausea, vomiting, diarrhea, and fatigue. To date, there have only been only two reported cases with skin manifestations as a side effect. We report a case of eruptive facial milia and comedones in the setting of dovitinib treatment for metastatic gastrointestinal cancer. This case is unique as the clinical presentation was more rapid in onset and showed an absence of inflammatory lesions. Although the pathogenesis for skin manifestations is presently unknown, we present this case to increase awareness of potentially under-reported cutaneous side effects.
authors.affiliation: San Antonio Military Medical Center, Fort Sam Houston.
authors.forename: Kate
authors.initials: K
authors.lastname: Kimes
authors.forename: Knox
authors.initials: K
authors.lastname: Beasley
authors.forename: Scott R
authors.initials: SR
authors.lastname: Dalton
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology; D005148:Facial Dermatoses / Q000139:chemically induced*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007642:Keratosis; D008297:Male; D008875:Middle Aged; D008883:Miliaria / Q000139:chemically induced*; D015363:Quinolones / Q000009:adverse effects*
chemical_list: C500007:4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D015363:Quinolones